Kornimate/medical-research-clean huggingface dataset:
nk activity modulation induced by intravenous lidocaine during colorectal laparoscopic surgery

Conditions: Colorectal Cancer

Summary: surgical resection is the best treatment option for colorectal cancer. despite this radical approach, recurrences within five years are still common. several authors have proposed that the immunosuppressive state surrounding the perioperative period was a key element of cancer cells spread. a particular subtype of t lymphocytes, the natural killer cells (nks), is the main actor of the innate immune system. several factors of the perioperative period can reduce activity of nks such as stress, pain, opioids and general anaesthetics. lidocaine is a local anaesthetic that has been widely used intravenously for abdominal surgeries. intravenous lidocaine has been shown to reduce pain scores, morphine consumption, ileus time and length of stay in major colorectal surgeries. it reduced markers of systemic inflammation as well. the authors hypothesize that the use of intravenous lidocaine during laparoscopic surgeries for colorectal cancer resection will preserve nks activity.


Eligibility criteria:
inclusion criteria: * patients admitted for resection of colorectal cancer under laparoscopic surgery * american society of anesthesiologists class i-iii. * the subject is able to understand the study objectives, the experimental protocol and procedures, and is capable of providing an informed consent. exclusion criteria: * subjects allergic to any of the study drugs. * bmi \> 35 kg/m2. * severe renal or hepatic failure. * pregnancy. * emergent procedure. * heart failure nyha \> iii. * systolic blood pressure \< 90 mmhg. * advanced heart block (unless patient has a pacemaker). * unstable angina and/or myocardial infarction within past 6 weeks. * fev1 ≤ 0.8 l. * oxygen-dependent patient. * electrocardiographic abnormalities * treatment with immunosupressive drugs, corticosteroids, nsaids, antiarythmic * morphine intolerance or allergy
comparison of color measurements of postgraduate dental students using different color determination methods

Conditions: Tooth Discoloration

Summary: this study evaluates the accuracy of tooth color identification skills in the anterior region using a new technique, the button technique, in comparison with other methods.

the human eye is effective in detecting subtle differences in tooth color. however, variations in the shade, translucency, opacity, and characterization of a tooth may not be accurately identified. visual color matching is subject to physiological variables that may lead to inconsistencies, such as age, gender, experience, the type of scale used, varying degrees of light exposure, eye fatigue, and color vision deficiency. studies comparing visual and instrumental methods have demonstrated that spectrophotometers yield better results compared to visual color scales. therefore, it is expected that color measurement devices improve the accuracy of tooth color determination, thereby enhancing the interpretation and aesthetic execution of restorations. in recent years, the button technique has been described for shade selection in direct aesthetic restorations in the anterior region. in this technique, small composite samples in the form of dots are polymerized on the tooth surface using a curing light. digital photographs are then taken, and appropriate enamel and dentin shades are selected on a computer using polarized and black-and-white images. very few clinical studies have investigated the use of digital color images obtained through intraoral digital scanners for shade selection, comparing them with other existing methods. the aim of this study is to evaluate the accuracy of shade determination skills in the anterior region by comparing a new technique, the button technique, with other methods and to recommend the most suitable method for shade selection

Eligibility criteria:
inclusion criteria: * being healthy individuals, * not having any systemic diseases, * being young individuals (18-40 age range) * vital, decay-free and healthy upper central teeth, * absence of caries-free hard tissue abrasions, any restoration, fracture, crack, intrinsic or extrinsic discoloration in the upper central teeth * lack of removable prosthesis feet for central teeth exclusion criteria: * tetracycline, fluorosis staining of upper central teeth * patients with dentin exposure or loss of bine in the upper central teeth for any reason * pregnant and lactating patients will not be included.

Keywords: color tooth button
study assessing pti-428 safety, tolerability, pharmacokinetics and effect in subjects with cystic fibrosis

Conditions: Cystic Fibrosis

Summary: the study population is comprised of adult subjects with cystic fibrosis (cf) who are homozygous for the f508del mutation and are currently receiving background treatment with tezacaftor/ivacaftor for a minimum of 1 month prior to day 1. the planned sample size is approximately 40 subjects. 20 subjects will be assigned to pti-428 dose level 1 or placebo and 20 subjects will be assigned to pti-428 dose level 2 or placebo. at each dose level, subjects will be randomized at a 3:1 randomization ratio. subjects will receive once daily oral doses of pti-428 or placebo for 28 days, while the subjects continue to receive background treatment with tezacaftor/ivacaftor per product label. the study drug administration period will be followed by a 14-day safety follow-up period.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of cf with the f508del/f508del genotype on record * on tezacaftor/ivacaftor dosing for both label indication and per label dosing for a minimum of 1 month on day 1 * forced expiratory volume in 1 second (fev1) 40-90% predicted, inclusive * clinically stable with no significant changes in health status within 14 days of day 1 * non-smoker and non-tobacco user for a minimum of 28 days prior to screening and for the duration of the study exclusion criteria: * participation in another clinical trial or treatment with an investigational agent within 28 days or 5 half-lives, whichever is longer, prior to study day 1 * history of cancer within the past 5 years (excluding cervical cancer in situ with curative therapy for at least one year prior to screening and non-melanoma skin cancer) * history of organ transplantation * hospitalization, sinopulmonary infection, cf exacerbation, or other clinically significant infection or illness (as determined by the investigator) requiring an increase or addition of medication, such as antibiotics or corticosteroids, within 14 days of day 1 * initiation of any new chronic therapy (e.g., ibuprofen, hypertonic saline, azithromycin, pulmozyme®, cayston®, tobi®)) or any change in chronic therapy (excluding pancreatic enzyme replacement therapy) within 28 days prior to day 1 * history or current evidence of alcohol or drug abuse or dependence within 12 months of screening as determined by the investigator * pregnant or nursing women
validation study of an advanced blood pressure monitor

Conditions: Atrial Fibrillation; Hypertension; Valvular Heart Disease

Summary: the proposed clinical study aims to validate the effectiveness of the wpm04 blood pressure monitor developed by withings as a diagnostic tool for cardiovascular disorders. the detection of cardiovascular disorders is oriented along three axes, namely the measurement of blood pressure, the identification of rhythm disorders such as atrial fibrillation and the identification of heart murmur indicating valvular heart disease.


Eligibility criteria:
inclusion criteria: * male or female over 18 years old, * subject who signed the consent form, * subject affiliated to a social security scheme or entitled. exclusion criteria: * underage subject; * subject who refused to participate in the study; * subject participating in other research or clinical studies; * subject with body mass index greater than 35 kg/m2; * subject in linguistic or psychic incapacity to sign an informed consent; * subject with congenital cardiomyopathy; * subject with aorto-venous fistula; * subject with pulmonary pathology that may degrade the quality of the recording; * subject presenting a serious pathology compromising the realization of the examinations envisaged in the test; * subject with an arm injury incompatible with the use of an armband sphygmomanometer; * subject receiving an intravenous perfusion on the left arm; * subject with electrical stimulation by pacemaker, implantable cardioverter-defibrillator; * subject with prosthetic heart valve; * subject under kidney dialysis; * hemodynamically unstable subject (acute heart failure or cardiac assistance).

Keywords: blood pressure arrhythmias, cardiac atrial fibrillation valvular disease blood pressure monitors electrocardiography doppler echocardiography heart diseases cardiovascular diseases
ecmo for critically ill patients with respiratory failure and/or circulatory failure

Conditions: Severe Acute Respiratory Distress Syndrome; Refractory Hypoxemia

Summary: extracorporeal membrane oxygenation (ecmo) had been used to treat refractory hypoxemia associated with acute respiratory distress syndrome (ards). there were reported good outcome associated with ecmo for ards caused by influenza infection from several ecmo centers. however, the outcome of ecmo support in lower ecmo experience center had not been evaluated. this study aimed to evaluate the outcome of ecmo, comparing with conventional treatment among severe hypoxemic ards patients who were admitted in limited ecmo experience hospital.

this registry enroll refractory hypoxemia ards patients who met the criteria for veno-venous ecmo, according to 2013 extracorporeal life support organization (elso) guideline criteria. the definition of refractory hypoxemia was partial pressure of oxygen:fraction of inspire oxygen (pao2/fio2) \ 90% despite optimal mechanical ventilator support for at least 2 hours. the ecmo team was alerted for patient evaluation. the patients, who did not consider as ecmo candidate, due to their underlying condition of terminally illness, were excluded. the decision to initiate ecmo, or not, is dependent on the conference included the patient or the patient first relative, the attending physician and the ecmo team physicians. patients who ecmo is initiated will be classified into ecmo group. patients who they or their 1st degree relative do not agree for ecmo initiation will be treated according to standard treatment for ards, and classified in non-ecmo group. the patients in both groups will be follow up until they are discharged from the hospital.

Eligibility criteria:
inclusion criteria: * diagnosed ards according to berlin criteria * refractory hypoxemia: pao2/fio2 \ 90% despite optimal mechanical ventilator support and paralytic agent infusion * hypoxemia persist for at least 2 hours exclusion criteria: * terminally ill patient * patient who sign for do not resuscitation * metastatic malignancy

Keywords: veno-venous ecmo severe ards refractory hypoxemia
effects of transcutaneous acupoint electrical stimulation on postoperative hrv and hs-ctnt of elderly with chd

Conditions: Coronary Artery Disease; Anesthesia

Summary: the aim of this study was to observe the effect of transcutaneous acupoint electrical stimulation (taes) on postoperative heart rate variability and high-sensitive cardiac troponin t of elderly patients with coronary heart disease.

general anesthesia can inhibit sympathetic nerve activity and attenuate stress response, but it also inhibits vagus nerve activity. the decrease of vagus nerve activity can cause cardiovascular complications, especially ventricular arrhythmia in patients with coronary heart disease. some study have shown that electrical stimulation of transcutaneous acupoints can regulate the function of autonomic nervous system and enhance the activity of vagus nerve so as to protect myocardial tissue. but the effect on autonomic nervous function and myocardial injury markers in elderly patients with coronary heart disease was not reported. heart rate variability (hrv) is a noninvasive and reliable index reflecting cardiac autonomic nervous function. high-sensitive cardiac troponin hs-ctnt is the best myocardial injury marker. the investigators plan to recruite 150 patients with coronary heart disease of both sexes, aged 65-80 yr, undergoing elective lumbar decompression and fusion internal fixation surgery. they will be randomly divided into 2 groups(n=75 each)using random number table : control group ( group c ) and taes group (group t). patients in group t receive teas (disperse-dense waves, frequency 4/20hz) at the points of pc6 (neiguan) and pc4 (ximen) from 30 min before anesthesia induction to the end of surgery, the optimal intensity will be adjusted to maintain a slight twitching of the midfinger or ring finger (de-qi response). patients in group c receive electrode plate at the same acupoints without any electrical stimulation. heart rate variability will be collected on 1 day before surgery, 1, 3 and 5d after surgery. 3ml of venous blood will be collected before the induction of anesthesia, 1, 3 and 5d after surgery, the serum will be isolated for the measurement of serum concentration of high-sensitive troponin t (hs-ctnt)、ck、crp.

Eligibility criteria:
inclusion criteria: * stable angina pectoris * slilent myocardial ischemia * remote myocardial infarction exclusion criteria: * congenital heart disease * have a history of cardiac surgery * frequent ventricular / atrial premature beats, atrial fibrillation and other serious arrhythmia * heart conduction diseases * antiarrhythmic drugs used * temporary and permanent pacemaker used * intraoperative blood loss\>800ml

Keywords: anesthesia, general
tinnitus treatment with piribedil guided by acoustic otoemissions and electrocochleography

Conditions: Tinnitus

Summary: tinnitus is defined as the perception of sound in the absence of a external source. about 15 % of the population is believed to experience tinnitus and for about 20 % of them it may become a very serious problem. total comprehension of tinnitus pathophysiology has not yet been achieved, but modern theories focus in brain hyperactivity following inner ear damage, with involvement of various neurotransmitters. piribedil,a dopamin agonist, has been used to treat tinnitus, focusing in dopamine release, which is inhibitory. electrophysiological methods,like acoustic otoemissions and electrocochleography may reveal the changes in peripherical and central auditory pathways and help to choose the specific patients who could benefit from piribedil treatment.


Eligibility criteria:
inclusion criteria: * tinnitus for more than 6 months * thi \> 38 * no central acting drugs in the last 6 months * tympanogram type a-n exclusion criteria: * vascular and muscular tinnitus * concomitant tmj disorders * abnormal otoscopy * mixed and conductive hearing losses

Keywords: tinnitus piribedil acoustic otoemissions ecog
laser vaginal treatment for sui

Conditions: Stress Urinary Incontinence

Summary: rct designed to answer the question: does the application of erbium: yag laser treatment to the vagina improve urine control for women with sui?

this is a double blinded randomized controlled clinical trial with a treatment arm and a sham treatment arm followed by an open label trial at 6 months for any sham treatment arm participants who do not meet treatment success. the primary goal is to compare the subjective success rates for the resolution of ui for the vaginal laser treatment at 6 months. secondary aims include an assessment of complications, resolution of sui symptoms (objective and subjective measures), patient bother from ui, quality of life and patient satisfaction. the proposed sample size is 182 patients. at the 6-month post treatment evaluation, the treatment allocation will be unmasked. the trial will be of approximately 3 years in duration (1 year to recruit and 2 years for follow up).

Eligibility criteria:
inclusion criteria: 1. female patient, aged 18 years or older at the time of enrollment, 2. primary symptoms of sui, as confirmed by patient medical history and clinical symptoms, including a focused incontinence evaluation; for a duration of at least 3 months (patient can be rescreened after this time interval has passed). 3. the patient agrees to no new parallel treatment for sui during the treatment period and the 6 months following it. 4. objective proof of sui: observation of urine leakage by cough and valsalva (positive stress test) at a bladder volume of ≤ 300cc 5. bladder capacity ≥200cc 6. post void residual ≤100cc with stage i or lower pelvic organ prolapse exclusion criteria: 1. patient is pregnant, lactating, or plans to become pregnant during the course of the study; or patient is \<12 months post partum 2. patient has other predominant type of ui (eg urgency ui, overflow ui, fistula) 3. patient has a vaginal condition that does not allow proper vaginal placement of the laser probe in its protective speculum 4. current chemo/ radiotherapy; history of pelvic radiation 5. systemic diseases known to affect bladder function (eg parkinson's disease, multiple sclerosis, spina bifida, spinal cord injury) 6. current or history of urethral diverticulum, prior augmentation cystoplasty, implanted nerve stimulators for bladder symptoms 7. history of synthetic sling 8. pelvic surgery \< 3 months 9. current evaluation or treatment for chronic pelvic pain 10. patient has pelvic organ/ vaginal prolapse extending to or out of the vaginal opening 11. participation in another treatment intervention that might interfere with the results of this trial 12. patient has a medical condition or disorder that may limit life expectancy or that may cause non-compliance with the protocol (e.g. unable to perform self-evaluations and/or accurately report medical history, urinary symptoms, and/or data). 13. patient has ambulatory 24 hour pad test, where the increased pad weight is \< 3 grams. 14. patient is non-ambulatory (ambulatory with assistive devices allowed)

Keywords: laser treatment
characterization of proteoglycan depletion in femoroacetabular impingement with t1ρ magnetic resonance imaging (mri)

Conditions: Femoroacetabular Impingement; Cartilage, Articular; Hip Joint; MRI

Summary: magnetic resonance imaging (mri) has proven to be one of the best ways to image articular cartilage. a tremendous amount of research has focused on cartilage imaging with an emphasis of early-osteoarthritis (oa) characterization. one of the techniques which has shown great promise is the imaging technique called t1ρ . the advantage of this pulse sequence is that it is sensitive to proteoglycans (pg), a major macromolecule degraded in oa. the study objective is to determine if t1ρ can acutely assess pg content in femoroacetabular impingement (fai) which may allow physicians to differentiate between normal and early-oa cartilage states in fai patients.

magnetic resonance imaging (mri) is one of the best ways to image articular cartilage. one of the techniques which has shown great promise is the imaging technique called t1ρ (t1-rho). t1ρ is a modified pulse sequence from the standard t1 sequence used in the clinical mri. because the initial phases of arthritis occur at the molecular level, the main advantage of the t1ρ pulse sequence is that it is sensitive to proteoglycan. proteoglycan is a molecule that is important to cartilage structure, and is lost as osteoarthritis develops. if we can show that this non-invasive tool can accurately assess cartilage damage and levels of proteoglycan, the clinical applications are numerous. the results can potentially help determine optimal surgical techniques and timing of surgical intervention to halt or slow the progression of arthritis, and will assist in the study of the effects of fai and the success of the surgery performed to correct fai.

Eligibility criteria:
inclusion criteria: * group 1: patient has been diagnosed by the surgeon as having femoro-acetabular impingement (fai) of the hip) * group 1: must meet all the following criteria: a) history and physical exam 1) intermittent pain worse with activity 2) positive impingement test (pain with flexion, adduction, and internal rotation of affected hip) b) x-ray 1) no signs of oa on plain radiological films (i.e. no osteophytes, no loss of joint space) 2) non-spherical femoral head * group 2: patient has not been diagnosed by the surgeon as having any hip problems. exclusion criteria: * previous hip surgeries (pelvic osteotomies) * previous hip trauma * history of pediatric hip pathology: slipped capital femoral epiphysis or hip dysplasia * over the age of 40 years
written disclosure therapy for anxiety and stress in patients with chronic lung disease

Conditions: Chronic Lung Diseases; COPD; Pulmonary Fibrosis

Summary: the purpose of this study is to determine whether written disclosure therapy (wdt) is of any benefit to patients with chronic lung diseases who are participating in pulmonary rehabilitation.

chronic lung diseases are typically associated with impaired quality of life, stress, and anxiety. written disclosure therapy (wdt) reduces stress in patients with a variety of chronic illnesses. we sought to determine if written disclosure therapy benefits patients with chronic lung diseases when it is added as a component to the pulmonary rehabilitation program.

Eligibility criteria:
inclusion criteria: * diagnosis of copd or pulmonary fibrosis * first time participants in pulmonary rehabilitation program exclusion criteria: * dementia * prior significant psychiatric illness * inability to complete the questionnaires * inability cooperate with spirometry * inability or to participate in outpatient follow-up over the six-month

Keywords: dyspnea written disclosure therapy copd pulmonary fibrosis chronic lung diseases pulmonary rehabilitation
infectious complications after cystectomy: a prospective observational study

Conditions: Bladder Cancer; Infections; Infection, Bacterial; Infection, Hospital; Infection Wound; Urinary Tract Infections; Urinary Bladder Diseases; Urinary Tract Disease

Summary: patients undergoing cystectomy for either oncological or non-oncological indications are prospectively enrolled following informed consent. this study design incorporates a comprehensive medical history, detailed prospective documentation of clinicopathological parameters, and serial measurements of infectious markers pre- and post-operatively. in-hospital complications are meticulously recorded, and long-term outcomes assessed through structured follow-up interviews at 3, 6, and 12 months. these follow-ups utilize standardized questionnaires to evaluate post-discharge infectious complications and gather patients' perspectives on their in-hospital experiences, providing a robust understanding of both clinical outcomes and patient-reported experiences.

aims of the study: 1. prospective evaluation of the association between preoperative interleukin-6 levels and local tumor stage in patients undergoing radical cystectomy 2. prospective assessment of interleukin-6, procalcitonin and wound drainage culture as early indicators for perioperative infectious complications after cystectomy 3. prospective evaluation of physician-assessed vs. patient-reported grading of complications after cystectomy 4. prospective comparison of infectious complications within the first 12 months after cystectomy: ileal neobladder vs. ileal conduit 5. prospective evaluation of the association between in-hospital complications after cystectomy and quality of life after three months

Eligibility criteria:
inclusion criteria: * disease which requires removal of the urinary bladder exclusion criteria: * patient does not want to participate